Sign in Subscribe
United States. Securities and Exchange Commission

Allergan Inc. Submits SEC Filing (Form 8-K) for Material Corporate Changes

Strategic Insights

— 1 min read

Allergan Inc., a leading pharmaceutical company, has submitted a Securities and Exchange Commission (SEC) filing (Form 8-K) on January 12, 2015, pertaining to material corporate changes that may affect investors or security holders. This filing provides more current information on specified events than the company's quarterly or annual reports. The filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

Key Takeaways:

  • The SEC filing (Form 8-K) by Allergan Inc. reports material corporate changes that may affect investors or security holders.
  • The company submitted four documents with this form, providing more current information on certain specified events than quarterly or annual reports.
  • The SIC code for Allergan Inc. is 2834, Pharmaceutical Preparations, and the SEC file number is 0001193125-15-008100.
  • The contact information for Allergan Inc. is 2525 DUPONT DRIVE, IRVINE CA 92612, 7142464500.
  • Form 8-K is the "current report" used to report material events or corporate changes that are of importance to investors or security holders and previously have not been reported by the registrant.

Statistics:

  • The SEC filing (Form 8-K) was submitted on January 12, 2015.
  • There were 4 documents filed with this form.
  • The SIC code for Allergan Inc. is 2834.
  • The SEC file number is 0001193125-15-008100.
  • The contact information for Allergan Inc. includes a physical address and phone number.

Sources:

  • U.S. Securities and Exchange Commission (SEC) filing by Allergan Inc. (Form 8-K), Janet 12, 2015
  • NewsRx LLC, "Securities and Exchange Commission Filing (Form 8-K) - Allergan Inc."
  • Securities and Exchange Commission, "Form 8-K"

Read more